Ionis Pharmaceuticals, Inc. (IONS)

NMS – Real vaqt narxi. Valyuta: USD

75.83

+0.45 (0.60%)

Yopilishda: May 12, 2026, 4:00 PM EDT

75.48

-0.35 (-0.46%)

Bozor oldidan: May 13, 2026, 8:32 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Ionis Pharmaceuticals, Inc. (IONS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Ionis to host 2026 virtual Annual Meeting of Stockholders

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Videolar

Press-relizlar

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Search stocks

Ionis Pharmaceuticals, Inc. (IONS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Ionis to host 2026 virtual Annual Meeting of Stockholders

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Videolar

Press-relizlar

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting